Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

966
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
966
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

402
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
402
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

369
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
369

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selenoprotein deficiency disorder predisposes to aortic aneurysm formation.

Nature communications·2023
Same author

Failure to apply standard limit-of-detection or limit-of-quantitation criteria to specialized pro-resolving mediator analysis incorrectly characterizes their presence in biological samples.

Nature communications·2023
Same author

Oxalate disrupts monocyte and macrophage cellular function via Interleukin-10 and mitochondrial reactive oxygen species (ROS) signaling.

Redox biology·2023
Same author

Preventing mitochondrial reverse electron transport as a strategy for cardioprotection.

Basic research in cardiology·2023
Same author

MitoQ as an antenatal antioxidant treatment improves markers of lung maturation in healthy and hypoxic pregnancy.

The Journal of physiology·2023
Same author

Energy substrate metabolism, mitochondrial structure and oxidative stress after cardiac ischemia-reperfusion in mice lacking UCP3.

Free radical biology & medicine·2023

Related Experiment Video

Updated: Feb 14, 2026

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
07:13

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

6.9K

MitoQ improves mitochondrial dysfunction in heart failure induced by pressure overload.

Rogério Faustino Ribeiro Junior1, Erinne Rose Dabkowski2, Kadambari Chandra Shekar3

  • 1Division of Cardiology, Department of Medicine, University of Maryland, Baltimore, MD, USA; Department of Physiological Sciences, Federal University of Espirito Santo, Vitoria, ES, Brazil.

Free Radical Biology & Medicine
|February 9, 2018
PubMed
Summary

MitoQ treatment reduced heart failure symptoms in rats, improving mitochondrial function and decreasing harmful reactive oxygen species. This suggests MitoQ may be a promising therapeutic target for heart failure.

Keywords:
Heart failureInterfibrillar mitochondriaMitoQMitochondrial dysfunctionReactive oxygen speciesSubsarcolemmal mitochondria

More Related Videos

A Pulmonary Trunk Banding Model of Pressure Overload Induced Right Ventricular Hypertrophy and Failure
06:47

A Pulmonary Trunk Banding Model of Pressure Overload Induced Right Ventricular Hypertrophy and Failure

Published on: November 29, 2018

10.1K
Author Spotlight: Investigating the Underlying Mechanisms of Right Ventricular Failure in Pulmonary Hypertension
04:49

Author Spotlight: Investigating the Underlying Mechanisms of Right Ventricular Failure in Pulmonary Hypertension

Published on: June 14, 2024

1.2K

Related Experiment Videos

Last Updated: Feb 14, 2026

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
07:13

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

6.9K
A Pulmonary Trunk Banding Model of Pressure Overload Induced Right Ventricular Hypertrophy and Failure
06:47

A Pulmonary Trunk Banding Model of Pressure Overload Induced Right Ventricular Hypertrophy and Failure

Published on: November 29, 2018

10.1K
Author Spotlight: Investigating the Underlying Mechanisms of Right Ventricular Failure in Pulmonary Hypertension
04:49

Author Spotlight: Investigating the Underlying Mechanisms of Right Ventricular Failure in Pulmonary Hypertension

Published on: June 14, 2024

1.2K

Area of Science:

  • Cardiovascular Research
  • Mitochondrial Biology
  • Pharmacology

Background:

  • Heart failure is a growing public health concern with limited therapeutic options.
  • Mitochondrial dysfunction is a key factor in heart failure progression.
  • Current treatments offer poor prognosis, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To investigate the therapeutic potential of MitoQ in mitigating pressure overload-induced heart failure.
  • To analyze the effects of MitoQ on cardiac function, mitochondrial integrity, and oxidative stress.
  • To evaluate MitoQ's impact on mitochondrial respiration and calcium handling in a rat model.

Main Methods:

  • Induction of heart failure via pressure overload in rats for 14 weeks.
  • Administration of MitoQ (100 µM) in drinking water to assess its protective effects.
  • In vivo and ex vivo assessments of cardiac function, ventricular hypertrophy, and lung congestion.
  • Mitochondrial isolation for analysis of membrane potential, protein content, respiration, and calcium retention capacity.

Main Results:

  • MitoQ treatment reduced right ventricular hypertrophy and lung congestion in heart failure rats.
  • MitoQ restored mitochondrial membrane potential and improved mitochondrial respiration.
  • MitoQ decreased hydrogen peroxide production and improved mitochondrial calcium retention capacity.

Conclusions:

  • MitoQ effectively ameliorates mitochondrial dysfunction in pressure overload-induced heart failure.
  • The compound demonstrates potential in reducing oxidative stress and improving bioenergetics.
  • MitoQ represents a promising therapeutic agent for managing heart failure by targeting mitochondrial health.